Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
$0.66
-1.5%
$21.77
$0.51
$10.55
$4.89M0.933.15 million shs11,539 shs
Kaya Holdings, Inc. stock logo
KAYS
Kaya
$0.04
+34.5%
$0.04
$0.03
$0.09
$430K0.583,031 shs30,880 shs
NRIFF
Nuvo Pharmaceuticals
$0.75
$0.30
$0.87
$8.52M1.577,337 shs3,000 shs
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
$13.52
$8.80
$36.88
$8.65M0.83543,436 shs988,300 shs
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
$0.22
$0.22
$0.08
$0.34
$56.90M2.65,474 shsN/A
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
0.00%+13.56%-7.84%+33.44%-56.21%
Kaya Holdings, Inc. stock logo
KAYS
Kaya
+33.56%+25.81%-6.02%-12.46%-28.57%
NRIFF
Nuvo Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
0.00%0.00%0.00%0.00%0.00%
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/AN/AN/AN/AN/AN/AN/AN/A
NRIFF
Nuvo Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
N/AN/AN/AN/A
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/AN/AN/AN/A
NRIFF
Nuvo Pharmaceuticals
N/AN/AN/AN/A
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
N/AN/AN/AN/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
N/AN/AN/AN/A$2.01 per shareN/A
Kaya Holdings, Inc. stock logo
KAYS
Kaya
$200K2.87$0.17 per share0.23($1.07) per share-0.04
NRIFF
Nuvo Pharmaceuticals
$52.41M0.00N/A0.82$1.59 per share0.00
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
N/AN/AN/AN/A$16.18 per shareN/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
$7.38M7.71N/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
-$27.12M-$3.464.39N/AN/AN/A36.08%27.40%N/A
Kaya Holdings, Inc. stock logo
KAYS
Kaya
$1.61M-$0.02N/AN/A821.43%-9.57%638.26%4/26/2024 (Estimated)
NRIFF
Nuvo Pharmaceuticals
$2.53M$0.0418.69N/AN/A-2.81%8.02%1.11%N/A
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
-$14.13M-$16.32N/AN/AN/AN/A-96.37%-68.87%N/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
-$18.79M-$0.08N/AN/A-254.66%-346.72%-94.54%N/A

Latest NTEC, KAYS, ANCN, NRIFF, and TRLPF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/16/2024Q4 2023
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/A$0.01+$0.01$0.01N/A$0.03 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
N/AN/AN/AN/AN/A
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/AN/AN/AN/AN/A
NRIFF
Nuvo Pharmaceuticals
N/AN/AN/AN/AN/A
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
N/AN/AN/AN/AN/A
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
N/A
3.25
3.25
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/A
0.01
0.01
NRIFF
Nuvo Pharmaceuticals
5.27
2.67
2.11
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
N/A
2.34
2.34
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
0.64
1.35
0.90

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
9.05%
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/A
NRIFF
Nuvo Pharmaceuticals
N/A
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
22.37%
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
0.02%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Anchiano Therapeutics Ltd. stock logo
ANCN
Anchiano Therapeutics
167.42 millionN/ANot Optionable
Kaya Holdings, Inc. stock logo
KAYS
Kaya
414.72 million11.26 millionNot Optionable
NRIFF
Nuvo Pharmaceuticals
9911.40 millionN/ANot Optionable
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
40898,000N/AOptionable
Acerus Pharmaceuticals Co. stock logo
TRLPF
Acerus Pharmaceuticals
29258.62 millionN/ANot Optionable

NTEC, KAYS, ANCN, NRIFF, and TRLPF Headlines

SourceHeadline
Takeda Pharmaceutical Co. Ltd. ADRTakeda Pharmaceutical Co. Ltd. ADR
wsj.com - February 8 at 10:03 AM
Other OTC Pharmaceuticals - LithuaniaOther OTC Pharmaceuticals - Lithuania
statista.com - September 17 at 1:59 AM
2023 A Big Year For Testosterone: AbbVie And ANI Pharmaceuticals Best Positioned To Benefit2023 A Big Year For Testosterone: AbbVie And ANI Pharmaceuticals Best Positioned To Benefit
seekingalpha.com - January 1 at 9:14 AM
Acerus Reports Second Quarter 2022 Financial ResultsAcerus Reports Second Quarter 2022 Financial Results
financialpost.com - August 9 at 7:47 AM
Acerus Reports Fourth Quarter and Full Year 2021 Financial ResultsAcerus Reports Fourth Quarter and Full Year 2021 Financial Results
financialpost.com - March 15 at 7:47 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Anchiano Therapeutics logo

Anchiano Therapeutics

NASDAQ:ANCN
Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.
Kaya logo

Kaya

OTCMKTS:KAYS
Kaya Holdings, Inc., a vertically integrated legal cannabis enterprise, produces, distributes, and/or sells a range of cannabis products primarily in the United States. The company offers flower, oils, vape cartridges and cannabis infused confections, baked goods, and beverages. It also operates retail outlets under the Kaya Shack brand name, as well as offers strain specific cannabis cigarettes under the Kaya Buddies name, and strains of cannabis under the Kaya Farms name. In addition, the company provides standing display cases with cannabis intended glassware under the Really Happy Glass brand; and t-shirt designs under the Kaya Gear brand name. The company was formerly known as Alternative Fuels America, Inc. and changed its name to Kaya Holdings, Inc. in April 2015. Kaya Holdings, Inc. was incorporated in 1993 and is headquartered in Fort Lauderdale, Florida.

Nuvo Pharmaceuticals

OTCMKTS:NRIFF
Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. Nuvo Pharmaceuticals was founded on August 22, 1983 and is headquartered in Mississauga, Canada.
Intec Pharma logo

Intec Pharma

NASDAQ:NTEC
Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel.
Acerus Pharmaceuticals logo

Acerus Pharmaceuticals

OTCMKTS:TRLPF
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.